When it comes to radiation therapy to treat brain cancer, hippocampal-avoidance whole-brain radiotherapy in conjunction with the drug memantine better preserved patients’ cognitive function and demonstrated similar cancer control outcomes, compared to traditional whole-brain radiotherapy with memantine. These findings were presented on Tuesday, Oct. 23, by Mayo Clinic researchers at the 2018 annual meetingof the American Society for Radiation Oncology (ASTRO) in San Antonio. “The hippocampus is a part of the brain associated with the
Results of two phase 2 clinical trials testing cabozantinib suggest that anti-angiogenic therapy could be used to treat glioblastomas Glioblastoma is an aggressive type of brain tumor that affects approximately 74,000 individuals across the world, annually. The current standard of treatment for this tumour type consists of surgical removal of the tumor, accompanied with radiation therapy and chemotherapy. Despite patients undergoing a rigorous treatment regimen, the rate of tumor recurrence
Biological clocks throughout the body play a major role in human health and performance, from sleep and energy use to how food is metabolized and even stroke severity. Now, Texas A&M University researchers found that circadian rhythms could hold the key to novel therapies for glioblastoma, the most prevalent type of brain cancer in adults—and one with a grim prognosis. Scientists in the Texas A&M Center for Biological Clocks Research (CBCR) determined that the timed production of
UCLA scientists have discovered a potential combination treatment for glioblastoma, the deadliest form of brain cancer in adults. The three-year study led by Dr. David Nathanson, a member of UCLA's Jonsson Comprehensive Cancer Center, found that the drug combination tested in mice disrupts and exploits glucose intake, essentially cutting off the tumor's nutrients and energy supply. This treatment then stimulates cell death pathways—which control the cancer cells' fate—and prevents the
A Yale research team has found that by tinkering with the surface properties of drug-loaded nanoparticles, they can potentially direct these particles to specific cells in the brain. By making nanoparticles bioadhesive, or “sticky,” the researchers have answered a long-standing question: Once you get the particles to the brain, how do you get them to interact with the cancer cells there? Their findings are published May 19 in Nature Communications.